Mar 31st 2020
  • Share:

BAART Programs Opens Two Outpatient, Opioid Addiction Treatment Programs in Washington

BayMark Health Services brand improves access to treatment for patients on the Olympic Peninsula.

BayMark Health Services announced the opening of two BAART Programs outpatient treatment facilities on the Olympic Peninsula in Washington state. The clinics are now accepting patients in Bremerton at 1520 NE Riddell Road and in Port Angeles at 716 S. Chase Street. BAART Programs provides safe, effective medication-assisted treatment (MAT) using all three FDA approved medications including methadone, buprenorphine and long acting naltrexone, combined with counseling and supportive services for those struggling with opioid use disorder.

During this time of incredible uncertainty due to the impact of Covid-19, the opioid epidemic also continues to wage war on Americans struggling with opioid use disorders. As essential medical providers, BAART Programs decided to open and will continue to provide services to those already in treatment as well as new patients in need of support to begin or reignite their journey to recovery.

Previously, patients who live in Port Angeles, Bremerton and across the peninsula had to travel significant distances, often daily, into Seattle or Tacoma to participate in medication-assisted treatment.   Methadone maintenance is widely known as the gold standard of care for those struggling with opioid addiction. To benefit from the structure an Opioid Treatment Program (OTP) provides its patients and to sustain their recovery, accessibility and consistency is key. In responding to Washington State’s request for proposal of services, BAART recognized the opportunity and established these programs in locations providing less barriers for attendance.

“BayMark, through our various brands, provides treatment for opioid use disorder which aims to match each patient with the best level of care for them.” noted David K. White, Ph.D., CEO of BayMark Health Services. “The success of medication-assisted treatment with methadone and buprenorphine is scientifically undeniable and the impact it will have on those we treat in the new BAART locations will be literally life-changing. We appreciated the opportunity to open programs in an area where treatment options for opioid addiction were truly limited and there is an identified need.”

BAART Programs are known across the country as providers of quality, comprehensive methadone and buprenorphine treatment. The Port Angeles and Bremerton programs will provide addiction education, relapse prevention, lab testing, coordinated care for pregnant patients and linkages to community resources to assist patients on their path to recovery. Our mission is to provide comprehensive medication-assisted treatment for opioid use disorder and other health care services to foster wellness, longevity and socially responsible behavior for the patients we serve.

Chief Operating Officer Frank Baumann added, “We are pleased to be bringing the BAART treatment model to Washington for the first time. Our medical, clinical and administrative staff offer compassionate, effective treatment to those struggling with this disease. We believe we can offer hope and healing to those individuals and their families.”

For more information on BAART visit: or contact:

BAART Programs Bremerton
Noel Webster, Treatment Center Director

BAART Programs Port Angeles
Rachel Anderson, Treatment Center Director

About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to more than 53,000 patients in recovery from substance use disorder across the United States and Ontario, Canada. Our outpatient programs deliver medically supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances. The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient office-based buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

Now Available: BayMark's 2023 Treatment Outcomes ReportGet the Whitepaper